Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events
Item8.01.
| Other Events. |
Minerva Neurosciences, Inc. (the Company) is filing the investor
presentation slides attached as Exhibit 99.1 to this Current
Report on Form 8-K which the Company may use from time to time in
conversations with investors and analysts. The presentation will
also be available on the investor relations section of the
Companys website.
Item9.01. |
Financial Statements and Exhibits. |
(d) |
Exhibits |
|
|
|
|
| 99.1 | Investor Presentation dated January 2017. |
About Minerva Neurosciences, Inc. (NASDAQ:NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein. Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information
Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session down -0.10 at 12.05 with 128,460 shares trading hands.
